This morning, Dr. Paul Bradley, co-founder and Chief Medical Officer of Scripta Insights, partner at BCG Medical Group, and Principal Investigator at Meridian Clinical Research’s internal medicine site in Savannah, Ga., dosed the very first patient in the nation’s first Phase 3 COVID-19 vaccine clinical trial. The trial is expected to enroll 30,000 adults to test the efficacy of a coronavirus vaccine developed by drugmaker Moderna.